Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates

Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conclusionsɤ-glutamyl hydroxymethyl rhodamine green fluorescence is a good postoperative prognostic indicator in patients with non-small cell lung cancer.
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Lung cancer remains the leading cause of cancer-related mortality worldwide [1]. The 5  year survival for patients with non-small cell lung cancer (NSCLC), the most common form of the disease, is 10−20% [2,3]. Despite advances in treatment options in recent years, survival rates have changed little [3,4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractCeritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor with clinical activity in crizotinib-resistant ALK-positive non-small cell lung cancer and in treatment-na ïve ALK-positive disease. Hyperglycemia is a known adverse event, but the mechanism by which ceritinib causes hyperglycemia is unknown, and whether ceritinib causes hyperglycemic emergencies is unclear. Here, we report the case of a patient with a hyperglycemic hyperosmolar state (HHS) recurrence a fter the re-administration of dose-reduced ceritinib. A 78-year-old man with type 2 diabetes diagnosed as having advanced lung adenoca...
Source: Diabetology International - Category: Endocrinology Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Electric Field Induced Release and Measurement (EFIRM) is a novel, plate based, liquid biopsy platform capable of detecting circulating tumor DNA containing EGFR mutations directly from saliva and plasma in both early and late stage patients with non-small cell lung cancer (NSCLC). We investigated the properties of the target molecule for EFIRM and determined that the platform preferentially detects single stranded DNA molecules. We then investigated the properties of the EFIRM assay and determined the linearity, linear range, precision, and limit of detection, for 6 different EGFR variants (the 4 most common g.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular Article Source Type: research
Publication date: Available online 31 May 2020Source: Materials Science and Engineering: CAuthor(s): Vineela Parvathaneni, Nishant S. Kulkarni, Gautam Chauhan, Snehal K. Shukla, Rasha Elbatanony, BrijeshKumar Patel, Nitesh K. Kunda, Aaron Muth, Vivek Gupta
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Propofol suppresses the progression of non‑small cell lung cancer via downregulation of the miR‑21‑5p/MAPK10 axis. Oncol Rep. 2020 May 21;: Authors: Wu X, Li X, Xu G Abstract Non‑small cell lung cancer (NSCLC) accounts for>80% of lung cancer cases and is the leading cause of cancer‑associated mortality worldwide. Propofol is an anesthetic drug frequently used during tumor resection. It is also known to exert inhibitory effects on cancer. Although the role of propofol in NSCLC has been reported, its underlying mechanisms remain unknown. The present study aimed therefore to investigate the m...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer